OBJECTIVE	To evaluate the efficacy of bicalutamide vs cyproterone acetate in preventing PSA flare ( as a surrogate for tumour flare ) for patients requiring luteinizing hormone-releasing hormone ( LHRH ) analogue therapy for prostate cancer .\